EudraCT Number: 2004-002050-66 Sponsor Protocol Number: PENTA 11 Start Date:
Sponsor Name: PENTA Foundation
Full Title: Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial
Medical condition: Infected with Human Immunodeficiancy Virus - (HIV-Infection)
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: IE (Ongoing) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2008-008435-29 Sponsor Protocol Number: 3082B2-4433-WW Start Date:
Sponsor Name: Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
Full Title: A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia...
Medical condition: Severe hemophilia A (FVIII:C
Disease: Version SOC Term Classification Code Term Level
14.0 10010331 - Congenital, familial and genetic disorders 10018937 Haemophilia A LLT
Population Age: Children, Under 18 Gender: Male
Trial protocol: FR (Completed) ES (Completed) IT (Completed) GR (Completed) CZ (Completed) SE (Completed) DK (Completed) FI (Completed) BG (Completed)
Trial results: View results
EudraCT Number: 2019-003370-35 Sponsor Protocol Number: MCT8-2019-2 Start Date:
Sponsor Name: Rare Thyroid Therapeutics International AB
Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency
Disease: Version SOC Term Classification Code Term Level
Population Age: Infants and toddlers, Children, Under 18 Gender: Male
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-000122-10 Sponsor Protocol Number: NS-065/NCNP-01-302 Start Date:
Sponsor Name: NS Pharma, Inc.
Full Title: A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
Medical condition: Duchenne Muscular Dystrophy (DMD)
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
Population Age: Children, Under 18 Gender: Male
Trial protocol: NL (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-005269-15 Sponsor Protocol Number: CO42865 Start Date:
Sponsor Name: F. Hoffmann-La Roche Ltd
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER
Medical condition: RET-mutated Medullary Thyroid Cancer (MTC)
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: SE (Ongoing) NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2017-004187-35 Sponsor Protocol Number: FACE-01 Start Date:
Sponsor Name: Falun Hospital
Full Title: The FACE (Facial nerve palsy And Cortisone Evaluation) study in children: a randomised double-blind, placebo-controlled, multicenter trial.
Medical condition: Facial Nerve Palsy (Bells Palsy)
Disease: Version SOC Term Classification Code Term Level
21.0 100000004852 10077335 Facial nerve paresis LLT
Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
Trial protocol: SE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-004691-37 Sponsor Protocol Number: Start Date:
Sponsor Name: St Vincents University Hospital
Full Title: Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients.
Medical condition: Psoriasis and Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2016-001898-32 Sponsor Protocol Number: V87_30 Start Date:
Sponsor Name: Seqirus UK Limited
Full Title: A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vacc...
Medical condition: Prophylaxis for Influenza virus
Disease: Version SOC Term Classification Code Term Level
20.0 10021881 - Infections and infestations 10022000 Influenza PT
Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
Trial protocol: EE (Ongoing) Outside EU/EEA
Trial results: (No results available)